Mixed trend on the daily chart: below its 200-day average, above its 50-day · 50-day below the 200-day · SuperTrend up since Aug 5 · above the Ichimoku cloud · RSI 65 · MACD above its signal
None of the 29 investors followed here reported a position in SHPH in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a SHPH trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jul 13, 2026 | Hrt Financial L.PBeneficial Owner of more than 10% of a Class of Security | Sale at price 2.96 - 4.48 per share. | 83.1K | $370.94K |
| Jul 9, 2026 | Hrt Financial L.PBeneficial Owner of more than 10% of a Class of Security | Purchase at price 3.11 - 3.38 per share. | 9K | $30.21K |
| Jul 7, 2026 | Hrt Financial L.PBeneficial Owner of more than 10% of a Class of Security | Sale at price 3.33 - 3.52 per share. | 29.1K | $100.46K |
| Jul 5, 2026 | Hrt Financial L.PBeneficial Owner of more than 10% of a Class of Security | Sale at price 3.51 per share. | 9K | $31.67K |
| Jul 1, 2026 | Hrt Financial L.PBeneficial Owner of more than 10% of a Class of Security | Purchase at price 3.54 per share. | 7.9K | $27.79K |
| Jun 30, 2026 | Hrt Financial L.PBeneficial Owner of more than 10% of a Class of Security | Purchase at price 3.30 per share. | 4K | $13.06K |
| Jun 29, 2026 | Hrt Financial L.PBeneficial Owner of more than 10% of a Class of Security | Purchase at price 3.23 - 3.44 per share. | 32.6K | $110.69K |
| Dec 30, 2024 | Schafer JoshuaDirector | — | 209.8K | — |
| Dec 30, 2024 | Richards Steven MDirector | — | 209.8K | — |
| Dec 22, 2024 | Schafer JoshuaDirector | — | 209.8K | — |
| Dec 22, 2024 | Richards Steven MDirector | — | 209.8K | — |
| Dec 22, 2024 | Brown MiltonDirector | — | 209.8K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 12.2 | -50.5 | -32.1 | 51.7 | -49.0 | -38.1 | 16.9 | -11.6 | 20.2 | 28.2 | −71.2% | ||
| 2025 | -12.3 | -19.1 | -36.1 | -31.4 | -34.5 | -13.9 | -3.1 | -9.6 | 7.6 | -16.3 | -51.9 | 25.9 | −91.6% |
| 2024 | -14.3 | 0.5 | 3.6 | 0.2 | 30.5 | -24.7 | 0.0 | -39.7 | -31.1 | 40.6 | -54.7 | 1.3 | −76.4% |
| 2023 | -5.1 | 1.1 | -29.3 | 24.1 | -32.7 | 3.5 | -21.7 | -17.8 | -17.6 | -23.1 | 6.6 | -9.0 | −76.8% |
| 2022 | -88.1 | -42.9 | -44.7 | 35.2 | −94.9% |
No analyst coverage for this instrument.
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to treat cancers. It owns a pharmaceutical software artificial intelligence (AI) driven platform for molecular discovery and early-stage drug development. The company was founded in 2012 and is headquartered in Gaithersburg, Maryland.